Novartis cancer drug meets main goal in Phase III study

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS) LBH589 drug for treating relapsed and refractory multiple myeloma, a bone marrow cancer, met its primary goal in a Phase III trial.

When combined with two other therapies, bortezomib and dexamethasone, LBH589 significantly increased progression-free survival in patients compared with those treatments alone.

Other companies working on drugs for multiple myeloma include Celgene (CELG)  and German firm MorphoSys (MPSYF). (PR)